pomalidomide has been researched along with Debility in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Kaisi, F; Anderson, L; Basker, N; Basu, S; Bygrave, C; Chauhan, SR; Djebbari, F; Eyre, TA; Gudger, A; Karim, F; Kothari, J; Lam, HPJ; Maddams, R; Morgan, L; Ngu, L; Obeidalla, A; Panitsas, F; Poynton, M; Prideaux, S; Ramasamy, K; Rampotas, A; Salhan, B; Sangha, G; Soutar, R; Triantafillou, M; Tsagkaraki, I; Vallance, G; Walker, M; Yang, L; Young, J | 1 |
| Choi, CW; Eom, HS; Kang, HJ; Kim, I; Kim, JS; Kim, K; Kim, MK; Kim, SJ; Lee, HS; Lee, JJ; Lim, SN; Min, CK; Mun, YC; Shin, HJ; Suh, C; Yoon, DH; Yoon, SS | 1 |
1 trial(s) available for pomalidomide and Debility
| Article | Year |
|---|---|
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dexamethasone; Drug Resistance, Neoplasm; Febrile Neutropenia; Female; Frail Elderly; Frailty; Hematologic Diseases; Humans; Incidence; Infections; Kaplan-Meier Estimate; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prednisone; Progression-Free Survival; Recurrence; Republic of Korea; Thalidomide | 2020 |
1 other study(ies) available for pomalidomide and Debility
| Article | Year |
|---|---|
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Frailty; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; United Kingdom | 2023 |